Global Cancer Registry Software Market Size Likely to Reach at a CAGR of 11.5% By 2033

As per the current market research conducted by the CMI Team, the global Cancer Registry Software Market size is expected to record a CAGR of 11.5% from 2024 to 2033. In 2024, the market size is projected to reach a valuation of USD 176.4 Million. By 2033, the valuation is anticipated to reach USD 469.8 Million.

Cancer Registry Software Market: Growth Factors and Dynamics

• Increasing Incidence of Cancer: The rising prevalence of cancer globally is a significant driver of the Cancer Registry Software Market. As the incidence of various types of cancer continues to grow, there is a greater need for efficient data management and analysis tools to track and monitor cancer cases, treatments, and outcomes.

• Regulatory Compliance Requirements: Stringent regulatory requirements for cancer reporting and data management drive the adoption of Cancer Registry Software solutions. Healthcare facilities, including hospitals and oncology centers, need to comply with regulations and accreditation standards, such as those set forth by the American College of Surgeons Commission on Cancer (CoC) in the United States, which mandate the use of certified cancer registry software.

• Advancements in Technology: Technological advancements, such as cloud computing, artificial intelligence, and big data analytics, are transforming the Cancer Registry Software Market. These innovations enable more efficient data collection, storage, analysis, and reporting, leading to improved accuracy, completeness, and accessibility of cancer registry data.

• Focus on Population Health Management: There is a growing emphasis on population health management strategies to address cancer prevention, early detection, and treatment outcomes. Cancer registry software plays a vital role in population health initiatives by providing comprehensive data analytics capabilities to identify trends, disparities, and opportunities for intervention in cancer care delivery.

• Interoperability and Data Sharing Initiatives: Increasing efforts to enhance interoperability and facilitate data sharing among healthcare stakeholders drive the adoption of Cancer Registry Software solutions. Integration with electronic health records (EHRs), health information exchanges (HIEs), and other health IT systems enables seamless data exchange, collaboration, and coordination of care across the cancer care continuum.

• Demand for Real-time Reporting and Surveillance: There is a growing demand for real-time reporting and surveillance capabilities in cancer registry software to support timely decision-making, epidemiological studies, and public health surveillance efforts. Healthcare organizations and public health agencies require agile and scalable software solutions that can capture, analyze, and disseminate cancer data rapidly to inform policymaking and resource allocation.

Cancer Registry Software Market: Partnership and Acquisitions

• In 2022, Elekta announced that the National Health Service Supply Chain (NHSSC) ordered multiple licenses for Elekta’s ProKnow software solution. ProKnow centralizes and analyzes radiotherapy data, offering secure, scalable access to NHS England’s radiation oncology facilities nationwide.

• In 2023, First Light Acquisition Group and Calidi Biotherapeutics, Inc. announced their merger to form a clinical-stage biotechnology company. Their focus is on developing oncolytic virotherapy using a stem cell-based cancer treatment delivery platform.

• In 2022, Gilead and Dragonfly have announced a research collaboration to advance natural killer cell engagers in oncology. Gilead obtained a worldwide license from Dragonfly for their 5T4 targeting immunotherapy program DF7001 as part of the agreement.

Report Scope

Cancer Registry Software Market: COVID-19 Analysis

The COVID-19 pandemic has had a significant impact on the Cancer Registry Software Market, with the industry experiencing both positive and negative effects. Here are some of the key impacts:

• Disruption of Cancer Care Services: The COVID-19 pandemic led to disruptions in cancer care services, including delays in cancer screenings, diagnoses, and treatments. Consequently, there was a decrease in the volume of cancer cases reported to cancer registries, affecting the completeness and accuracy of cancer registry data.

• Resource Constraints: Healthcare organizations faced resource constraints during the pandemic, including limited staffing, financial pressures, and competing priorities. These resource challenges hindered the implementation and maintenance of cancer registry software systems, leading to delays in data entry, analysis, and reporting.

• Resumption of Cancer Care Services: As healthcare systems stabilize and pandemic-related restrictions ease, efforts to resume and prioritize cancer care services will be crucial. Healthcare organizations need to prioritize cancer screenings, diagnoses, and treatments, ensuring the timely capture of cancer cases in registry systems.

• Enhanced Data Collection Efforts: Healthcare organizations can implement strategies to enhance data collection efforts, such as retrospective data abstraction and data reconciliation, to address gaps in cancer registry data caused by the pandemic-related disruptions. Leveraging technology-enabled solutions, such as natural language processing and machine learning, can facilitate efficient data abstraction and improve data completeness.

• Investment in Health IT Infrastructure: Organizations can invest in upgrading and expanding their health IT infrastructure, including cancer registry software systems, to enhance data management capabilities and support future resilience to external disruptions. Cloud-based solutions, interoperability standards, and data analytics tools can improve the agility, scalability, and interoperability of cancer registry software systems.

In conclusion, the COVID-19 pandemic has had a mixed impact on the Cancer Registry Software Market, with some challenges and opportunities arising from the pandemic.

List of the prominent players in the Cancer Registry Software Market:

• Elekta AB
• Cerner Corporation
• McKesson Corporation
• IBM Watson Health
• iSalus Healthcare
• Onco, Inc.
• MRS Systems Inc.
• Ordinal Data Inc.
• Rocky Mountain Cancer Data Systems Inc.
• Elekta AB
• Conduent Inc.
• Epic Systems Corporation
• Medstreaming LLC
• Flatiron Health Inc.
• Varian Medical Systems Inc.
• Others

The Cancer Registry Software Market is segmented as follows:

By Functionality

• Patient Management
• Treatment Planning
• Outcome Reporting
• Follow-up and Survivorship Care
• Quality Improvement

By Type of Cancer

• Breast Cancer
• Lung Cancer
• Prostate Cancer
• Colorectal Cancer
• Others

By Deployment Mode

• On-premises
• Cloud-based

By End User

• Hospitals
• Oncology Centers
• Government Organizations
• Research Institutes
• Others

Regional Coverage:

North America

• U.S.
• Canada
• Mexico
• Rest of North America

Europe

• Germany
• France
• U.K.
• Russia
• Italy
• Spain
• Netherlands
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• New Zealand
• Australia
• South Korea
• Taiwan
• Rest of Asia Pacific

The Middle East & Africa

• Saudi Arabia
• UAE
• Egypt
• Kuwait
• South Africa
• Rest of the Middle East & Africa

Latin America

• Brazil
• Argentina
• Rest of Latin America